Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
65M
-
Number of holders
-
0
-
Total 13F shares, excl. options
-
0
-
Shares change
-
-50.6M
-
Total reported value, excl. options
-
$0
-
Value change
-
-$202M
-
Number of sells
-
-85
Significant Holders of Inozyme Pharma, Inc. - Common Stock, par value $0.0001 per share (INZY) as of Q3 2025
87 filings reported holding INZY - Inozyme Pharma, Inc. - Common Stock, par value $0.0001 per share as of Q3 2025.
Inozyme Pharma, Inc. - Common Stock, par value $0.0001 per share (INZY) has 0 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 0 shares
of 65M outstanding shares and own 0% of the company stock.
Largest 10 shareholders include NISA INVESTMENT ADVISORS, LLC (0 shares), WOLVERINE ASSET MANAGEMENT LLC (0 shares), Vanguard Personalized Indexing Management, LLC (0 shares), CITIGROUP INC (0 shares), Mirae Asset Global Investments Co., Ltd. (0 shares), Sanofi (0 shares), Eukles Asset Management (0 shares), SBI Securities Co., Ltd. (0 shares), ALPINE ASSOCIATES MANAGEMENT INC. (0 shares), and Trium Capital LLP (0 shares).
This table shows the top 0 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.